Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 1

Integrating CAR T-Cell Therapy Into the Treatment Landscape for R/R DLBCL

,

Experts discuss the role of chimeric antigen receptor T-cell therapy (CAR T) in the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), how they sequence between bispecific antibodies and CAR T, the frequency and patient selection for CAR T in the second-line setting, and key takeaways from a recent oral presentation on real-world outcomes with axicabtagene ciloleucel (axi-cel) in the second-line setting from ASH 2024.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Integrating CAR T-Cell Therapy Into the Treatment Landscape for R/R DLBCL
    EP. 2: Bispecific Antibodies vs CAR T-Cell Therapy: Treatment Selection and Sequencing in Later-Line R/R DLBCL
    EP. 3: Selecting Candidates for CAR T-Cell Therapy in R/R DLBCL: Patient Characteristics, Eligibility, and Timing Considerations
    EP. 4: Expert Insights for Approaching Patient Counseling for CAR T-Cell Therapy in R/R DLBCL
    EP. 5: Practical Realities of CAR T-Cell Therapy for R/R DLBCL: Challenges and Lessons From the Community
    EP. 6: Optimal Strategies for Navigating Referral and Bridging Therapy for CAR T-Cell Therapy in R/R DLBCL Patients
    EP. 7: Safety Considerations for CAR T-Cell Therapy in R/R DLBCL
    EP. 8: Outpatient CAR T-Cell Therapy for R/R DLBCL: Opportunities, Challenges, and Solutions
    EP. 9: The Future of CAR T-Cell Therapy in R/R DLBCL: Closing Reflections and Key Takeaways

    Video content above is prompted by the following:

    • Where does CAR T-cell therapy currently fall into your treatment landscape for R/R DLBCL ?
    • How are you sequencing between bispecific antibodies and CAR T in the treatment of DLBCL?
    • With the approval of 2 agents after first-line therapy, how frequently are you utilizing CAR T in the second-line setting, and for which patients?
    • There was a recent oral presentation about real-world outcomes with axi-cel in the second-line setting from ASH 2024. What are your key takeaways from it and has it impacted your decision-making?
    x